• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Humoral Response to Leptospirosis Vaccination in Horses

August 6, 2017
Laurie Anne Walden, DVM, ELS

The authors of a new study believe vaccination is an important component in controlling leptospirosis in horses. Here’s why.

Leptospirosis vaccination significantly affects anti-Leptospira antibody production in horses, say the authors of a new study published in the Journal of Equine Veterinary Science. Although the humoral response was short-lived and was not apparently increased by booster vaccination, the investigators consider vaccination to be an important component of equine leptospirosis control.

In horses, leptospirosis can cause abortion and uveitis. Because equine Leptospira vaccines have not been widely available, prevention has traditionally focused on management techniques such as not feeding horses from the ground or allowing them to drink stagnant water.

Horses’ humoral responses to leptospirosis vaccines are not well understood, say the authors of the study, which was conducted in Brazil. They note that 1 equine multivalent leptospirosis vaccine is available in Brazil. (In the United States, the only leptospirosis vaccine currently licensed for use in horses is a monovalent vaccine against L. pomona.)

RELATED:

  • Tetravalent Vaccine Nobivac L4 Protects Against Leptospira
  • Key Features of Leptospirosis in Dogs

The study included 54 mares with no history of leptospirosis vaccination and no signs of uveitis. Thirty-six mares randomly assigned to the vaccination group received 2 doses of multivalent leptospirosis vaccine on days 0 and 40. Eighteen mares in the control group received no vaccination.

Advertisement

To identify natural infection in the study population, the investigators tested a random sample of 30 mares (15 in each group) on day 0 with urinary polymerase chain reaction testing. Tests from 2 mares in each group were positive, showing that they were renal carriers of leptospirosis.

The researchers conducted microscopic agglutination tests to detect humoral responses to specific Leptospira serovars. On day 0, 26 of 54 mares were seroreactive, with no significant different between groups. Seroreactivity in these mares was to L. australis and L. icterohaemorrhagiae.

By day 7, the percentage of seroreactive mares in the vaccination group had increased from 44.5% to 94.4%, and tests detected antigens to all 11 serovars included in the vaccine. This increase persisted for most serovars until day 60. The increase in the number of seroreactive horses was sustained to day 90 only for L. copenhagi, L. icterohaemorrhagiae, and L. pyrogenes.

In the control group, the percentage of seroreactive mares also significantly increased by day 7, although the increase was smaller (55.6% to 66.7%). By day 90, there was no significant difference in overall seroreactivity between the 2 groups. However, anti-Leptospira antibody titers were higher in vaccinated mares than in unvaccinated mares throughout the study period.

The investigators used enzyme-linked immunosorbent assay to identify immunoglobulin classes (IgG and IgM) in the mares’ serum. On day 0, the mares with Leptospira antibodies had a much higher concentration of circulating IgG than IgM, which the authors note is consistent with natural exposure. There was no significant difference between groups on day 0. In vaccinated mares, IgM increased relative to IgG over time. Both IgG and IgM were higher in vaccinated mares than in unvaccinated mares. By day 90, concentrations of both IgG and IgM had dropped in both groups.

An unexpected result was that booster vaccination (day 40) did not increase the number of seroreactive horses. Previous studies of leptospirosis vaccination in dogs, pigs, and cattle have shown the opposite effect, say the authors.

The authors note that the largest humoral responses were to serovars already present in the herd on day 0, suggesting that vaccination may have a booster effect. They add that different responses to different serovars is a limitation of multivalent vaccines.

Leptospirosis vaccination increased the percentage of seroreactive horses in the herd, conclude the authors. Other tests would be needed to show whether this effect represents true protection against leptospirosis. Vaccination caused no apparent adverse effects in any of the horses, so the authors recommend further studies of equine leptospirosis vaccination under field conditions.

Dr. Laurie Anne Walden received her doctorate in veterinary medicine from North Carolina State University. After an internship in small animal medicine and surgery at Auburn University, she returned to North Carolina, where she has been in small animal primary care practice for over 20 years. Dr. Walden is also a board-certified editor in the life sciences and owner of Walden Medical Writing, LLC. She works as a full-time freelance medical writer and editor and continues to see patients a few days each month.


Advertisement

Latest News

This week on dvm360.com: dvm360® continues to celebrate Pride Month, and other veterinary news

3 must-sees on creating an inclusive work culture

CityVet names new chief strategy officer

Workplace bottlenecks in the LGBTQIA+ community

View More Latest News
Advertisement